Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Telix Pharmaceuticals (TLX AU): Shares Are Bouncing off Lows; Driving Forces Behind and What’s Next

Telix Pharmaceuticals (TLX AU): Stellar H1 Financial Performance; Eye on Upcoming Approval

Telix Pharmaceuticals (TLX AU): Here’s Why Sentiment Has Improved

Telix Pharmaceuticals (TLX AU): Why Negative Impact of SEC Probe Is A Temporary Setback

Telix Pharmaceuticals (TLX AU): Strong Operating Performance in 3Q25; 2025 Guidance Raise

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/telix-pharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:26052:1" rel="noopener">Telix Pharmaceuticals (TLX AU)</a> reported 2025 revenue of $804M (~A$1.2B), slightly ahead of the lower range of the upgraded guidance range of $800–820M.</li>
<li>Telix shares reacted negatively to the result. No mention of 2026 guidance and any timeline for resubmission of NDA for Pixclara and Zircaix are the key negative takeaway.</li>
<li>In near term, Telix share performance is expected to remain muted. An update upon acceptance of the refiling of Pixclara and/or Zircaix will be next catalyst.</li>
</ul>



Telix Pharmaceuticals (TLX AU) reported 2025 revenue of $804M (~A$1.2B), slightly ahead of the lower range of the upgraded guidance range of $800–820M.
Telix shares reacted negatively to the result. No mention of 2026 guidance and any timeline for resubmission of NDA for Pixclara and Zircaix are the key negative takeaway.
In near term, Telix share performance is expected to remain muted. An update upon acceptance of the refiling of Pixclara and/or Zircaix will be next catalyst.


Telix Pharmaceuticals (TLX AU): Achieves 2025 Guidance; Geography and Portfolio Expansion on Card